CCL2 and neoplasm: In the multivariate Cox’s regression analysis (adjusted for tumor stage, lymph node stage, and molecular subtype), CCL2 staining was not associated with OS, but CT− patients with CCL2 negative staining possessed a 2.44-fold increased risk of disease-specific death (p = 0.010) and a 2.46-fold increased risk of relapse (p = 0.009) compared to CCL2-positive patients (Table 5).